Humanigen Inc (HGENQ)

[LongTkt]

Cross Check Lenzilumab Potential

I saw there are a few other clinical trials for anti GM-CSF treatments for COVID. Same method of action as Lenzilumab. None as far along as the Lenzilumab P3 clinical trial.

Gimsilumab

Namilumab

Mavrilimumab

Good to see other GM-CSF treatments have reported similar success as Lenzilumab. By that I mean that HGEN is not expected to be some type of epic failure when clinical trial results are announced.

Between March 17 and April 15, 2020, 13 non-mechanically ventilated patients (median age 57 years) received mavrilimumab and 26 patients (median age 60) in the control group received standard care.

During the 28-day follow-up, no patients in the mavrilimumab group died, and seven (27%) patients in the control group died.

At day 28, all patients in the mavrilimumab group and 17 (65%) patients in the control group showed clinical improvement, with earlier improvement in the mavrilimumab than in the control group (mean time to improvement 8 days vs 19 days).

By day 28, one (8%) patient in the mavrilimumab group progressed to mechanical ventilation compared with 9 (35%) patients in the control group who progressed to mechanical ventilation or died.

By day 14, fever resolved in 10 (91%) of 11 febrile patients in the mavrilimumab group, compared with 11 (61%) of 18 febrile patients in the control group; fever resolution was faster in mavrilimumab recipients versus controls (median time to resolution 1 day vs 7 days).

Mavrilimumab was well tolerated, with no infusion reactions.

Three (12%) patients in the control group developed infectious complications.

source


Good Article about GM-CSF and COVID
https://www.clinicaltrialsarena.com/comment/anti-gm-csf-antibodies-covid-19/